Pharma Deutschland Presses Berlin on AMNOG Reform Amid Rebate Hikes
Berlin – September 07, 2026 -- Germany's largest pharmaceutical trade association, Pharma Deutschland, has warned that new cost-containment measures under the GKV-BStabG threaten drug supply, innovation, and investment in the country, even as it welcomes a fresh round of government dialogue on AMNOG reform.
Federal Ministry convenes stakeholders for September 3 dialogue
The Federal Ministry of Health has invited industry representatives to an in-depth discussion on Thursday, September 3, 2026, focused on harmonizing Germany's drug pricing and assessment framework. Pharma Deutschland, which represents roughly 400 member companies employing about 80,000 people in Germany, said it backs the continuation of the Pharma- und Medizintechnik Dialog but insists selective bureaucratic fixes cannot offset broader damage from recent legislation.